StockData

Foghorn Therapeutics vs Fulcrum Therapeutics

FHTX and FULC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FHTX and FULC compare

Fulcrum Therapeutics is the larger company, worth 2.3 times as much as Foghorn Therapeutics ($285M against $124M).

Foghorn Therapeutics scores higher on the StockData Score (10 against 8 for Fulcrum Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFHTXFULC
Size and price
Market cap$124M$285M
Share price$2.09$3.74
Change, 1 year−52.7%−51.2%
Change, 5 years−84.7%−78.2%
Beta (5Y)1.871.57
Employees10655
StockData Score
Total score10 (better)8
Valuation score11
Growth score2 (better)0
Performance score2 (better)1
Health score56 (better)
Dividend score00
Valuation
P/E29.9×–
P/S1.1×–
P/B–0.9×
EV/EBITDA11.5×–
FCF yield−67.4%−23.2% (better)
Fair value$2.08–
Margin of safety−0.44%–
Growth
Revenue growth (TTM)357%–
Revenue growth, 5Y average135%–
Profitability
Operating margin2.1%–
Net margin8.4%–
FCF margin−74.6%–
Return on equity–−32.4%
Return on invested capital–−35.0%
Financial health
Debt / equity–0.00
Current ratio4.2431.35 (better)
Altman Z-score−2.6610.33 (better)
Piotroski F-score23 (better)
Dividends and buybacks
Buyback yield–−1.5%
Shareholder yield0.00% (better)−1.5%
Ownership
Held by institutions75.6%112%
Held by insiders36.3%34.7%
Insider net buying, 12 months–−$57.5M
Short interest, % of float6.0%12.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.